Journal of Clinical Psychiatry

Subject Index to Volume 54: January 1993 Through December 1993

Academic Highlights
Social phobia: an overview of treatment strategies. Apr 165–171
Neuroleptic-induced syndrome (NIDS). Dec 493–500
Understanding and treating psychoses: advances in research and therapy. Nov 445–452
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar 119–126

Addiction
Diagnostic limits of "addiction" [letter]. Satel; Stein DJ reply, June 237–238

Adolescents
Conduct disorder and personality disorders in hospitalized adolescents. Myers, Jan 21–26
Obsessive compulsive disorder in children and adolescents: issues in management. Rapoport, June suppl 27–29
Psychopharmacologic treatment of anxiety disorders in adolescents and children. Popper, May suppl 52–63

Adults
Prevalence of trichotillomania in a college freshman population [letter]. Rothbaum; Christenson reply, Feb 72–73

Affective Disorders see also Depression
Divalproex sodium in the treatment of refractory affective disorders. Schaff, Oct 380–384

Age
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202

Aggression
Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Ratey, June 219–223
Nadolol in the treatment of aggression in chronic psychiatric inpatients [letter]. Wong, June 235

Agoraphobia
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Hoffart, Dec 481–487
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Maddock, Mar 88–95

Agranulocytosis
HLA typing costs [letter]. Landy; Roerig reply, June 236–237

Akathisia
Akathisia and sertraline [letter]. Settle Jr, Aug 321
Akathisia as EPS [letter]. Pearlman; Opler reply, July 280
Iron for akathisia and persistent akathisia? [letter] Chengappa, Aug 320–321

Alcohol and Alcoholism
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Combined carbamazepine-buspirone treatment of alcohol dependence [letter]. de Oliveira, Dec 488
Preliminary data on seasonally related alcohol dependence. McGrath, July 260–262
Treating anxiety while minimizing abuse and dependence. Sussman, May suppl 44–51
Treatment of anxiety in patients with alcoholism. Frances RJ, May suppl 37–43

Alprazolam
Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. Cole, Oct suppl 49–61
Alprazolam and benzodiazepine dependence. Sellers, Oct suppl 64–75
Alprazolam and depression: a review of risks and benefits. Kravitz, Oct suppl 78–84
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Greenblatt, Oct suppl 4–14
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45
Overview. Issues in the clinical use of alprazolam. Ballenger, Oct suppl 3

Amantadine
Titration of serotonin reuptake blockers [letter]. Terao; Balogh reply; Hollander reply, Mar 115

***d*-Amphetamine**
d-Amphetamine versus methylphenidate effects in depressed inpatients. Little, Sept 349–355

Anorexia Nervosa
Zinc deficiency and childhood-onset anorexia nervosa. Lask, Feb 63–66

Anticholinergic Agents
Cardiac arrest during ECT: a cholinergic phenomenon? [letter] Liebowitz NR, July 279–280
Contribution of anticholinergic medication to symptom change in schizophrenia [letter]. DeQuardo; Serban reply, Sept 356–357

Anticonvulsants
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41

Antidepressant Drugs
Acute therapy of depression. Bech, Aug suppl 18–27
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202
Adverse drug reactions/interactions in maintenance therapy. Tollefson, Aug suppl 48–58
Antidepressant maintenance medications: when to discontinue and how to stop. Greden, Aug suppl 39–45
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Comparative pharmacology of new antidepressants. Leonard, Aug suppl 3–15; Correction, Dec 491
Monitoring antidepressant-induced cerebral hyperexcitability [letter]. Forstl; Preskorn reply, May 201–202
New antidepressants: use in high-risk patients. Hale, Aug suppl 61–70
Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Preskorn, Sept suppl 14–34
Primary care perspective on management of acute and long-term depression. Stokes, Aug suppl 74–84
Review of the cardiovascular effects of heterocyclic antidepressants. Glassman, Feb suppl 16–22
Seizures associated with antidepressants: a review. Rosenstein, Aug 289–299
Sexual dysfunction during antidepressant treatment. Balon, June 209–212
Use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. Altamura, Aug suppl 29–37
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar Academic Highlights 119–126

Antipsychotic Drugs
Dose response of prophylactic antipsychotics. Davis, Mar suppl 24–30
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41

Anxiety
Approaches to developing new anxiolytics and antidepressants. Dubovsky, May suppl 75–83
Beyond signs and symptoms: the case against a mixed anxiety and depression category. Preskorn, Jan suppl 24–32
Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Wittchen, Jan suppl 9–15
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45

Journal of Clinical Psychiatry

Subject Index to Volume 54: January 1993 Through December 1993

Academic Highlights
Social phobia: an overview of treatment strategies. Apr 165–171
Neuroleptic-induced syndrome (NIDS). Dec 493–500
Understanding and treating psychoses: advances in research and therapy. Nov 445–452
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar 119–126

Addiction
Diagnostic limits of "addiction" [letter]. Satel; Stein DJ reply, June 237–238

Adolescents
Conduct disorder and personality disorders in hospitalized adolescents. Myers, Jan 21–26
Obsessive compulsive disorder in children and adolescents: issues in management. Rapoport, June suppl 27–29
Psychopharmacologic treatment of anxiety disorders in adolescents and children. Popper, May suppl 52–63

Adults
Prevalence of trichotillomania in a college freshman population [letter]. Rothbaum; Christenson reply, Feb 72–73

Affective Disorders see also Depression
Divalproex sodium in the treatment of refractory affective disorders. Schaff, Oct 380–384

Age
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202

Aggression
Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Ratey, June 219–223
Nadolol in the treatment of aggression in chronic psychiatric inpatients [letter]. Wong, June 235

Agoraphobia
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Hoffart, Dec 481–487
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Maddock, Mar 88–95

Agranulocytosis
HLA typing costs [letter]. Landy; Roerig reply, June 236–237

Akathisia
Akathisia and sertraline [letter]. Settle Jr, Aug 321
Akathisia as EPS [letter]. Pearlman; Opler reply, July 280
Iron for akathisia and persistent akathisia? [letter] Chengappa, Aug 320–321

Alcohol and Alcoholism
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Combined carbamazepine-buspirone treatment of alcohol dependence [letter]. de Oliveira, Dec 488
Preliminary data on seasonally related alcohol dependence. McGrath, July 260–262
Treating anxiety while minimizing abuse and dependence. Sussman, May suppl 44–51
Treatment of anxiety in patients with alcoholism. Frances RJ, May suppl 37–43

Alprazolam
Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. Cole, Oct suppl 49–61
Alprazolam and benzodiazepine dependence. Sellers, Oct suppl 64–75
Alprazolam and depression: a review of risks and benefits. Kravitz, Oct suppl 78–84
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Greenblatt, Oct suppl 4–14
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45
Overview. Issues in the clinical use of alprazolam. Ballenger, Oct suppl 3

Amantadine
Titration of serotonin reuptake blockers [letter]. Terao; Balogh reply; Hollander reply, Mar 115

***d*-Amphetamine**
d-Amphetamine versus methylphenidate effects in depressed inpatients. Little, Sept 349–355

Anorexia Nervosa
Zinc deficiency and childhood-onset anorexia nervosa. Lask, Feb 63–66

Anticholinergic Agents
Cardiac arrest during ECT: a cholinergic phenomenon? [letter] Liebowitz NR, July 279–280
Contribution of anticholinergic medication to symptom change in schizophrenia [letter]. DeQuardo; Serban reply, Sept 356–357

Anticonvulsants
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41

Antidepressant Drugs
Acute therapy of depression. Bech, Aug suppl 18–27
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202
Adverse drug reactions/interactions in maintenance therapy. Tollefson, Aug suppl 48–58
Antidepressant maintenance medications: when to discontinue and how to stop. Greden, Aug suppl 39–45
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Comparative pharmacology of new antidepressants. Leonard, Aug suppl 3–15; Correction, Dec 491
Monitoring antidepressant-induced cerebral hyperexcitability [letter]. Forstl; Preskorn reply, May 201–202
New antidepressants: use in high-risk patients. Hale, Aug suppl 61–70
Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Preskorn, Sept suppl 14–34
Primary care perspective on management of acute and long-term depression. Stokes, Aug suppl 74–84
Review of the cardiovascular effects of heterocyclic antidepressants. Glassman, Feb suppl 16–22
Seizures associated with antidepressants: a review. Rosenstein, Aug 289–299
Sexual dysfunction during antidepressant treatment. Balon, June 209–212
Use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. Altamura, Aug suppl 29–37
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar Academic Highlights 119–126

Antipsychotic Drugs
Dose response of prophylactic antipsychotics. Davis, Mar suppl 24–30
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41

Anxiety
Approaches to developing new anxiolytics and antidepressants. Dubovsky, May suppl 75–83
Beyond signs and symptoms: the case against a mixed anxiety and depression category. Preskorn, Jan suppl 24–32
Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Wittchen, Jan suppl 9–15
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45

Depression with anxiety and atypical depression. Liebowitz MR, Feb suppl 10–14
Diagnostic considerations and treatment approaches to underlying anxiety in the medically ill. Wise, May suppl 22–26
Fluoxetine efficacy in social phobia. Van Ameringen, Jan 27–32
Heritability of social anxiety: a brief review. Fyer, Dec suppl 10–12
How to manage anxious patients who are depressed. Sussman, May suppl 8–16
Introduction. Part I. Treatment strategies for complicated anxiety. Frances AJ, May suppl 3
Introduction. Part II. Treatment strategies for complicated anxiety. Rakel, May suppl 21
Introduction. Social phobia in review: 1993. Davidson, Dec suppl 3–4
Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. Barbee, Oct suppl 86–97
Mixed anxiety and depression: clinical implications. Stahl, Jan suppl 33–38
Mixed anxiety and depression: diagnostic issues. Boulenger, Jan suppl 3–8
Mixed anxiety and depression: should it be included in DSM-IV? Liebowitz MR, May suppl 4–7
Neurobiological basis of mixed depression-anxiety states. Gulley, Jan suppl 16–19
Psychopharmacologic treatment of anxiety disorders in adolescents and children. Popper, May suppl 52–63
Psychopharmacologic treatment of anxiety in the medically ill elderly patient: special considerations. Stoudemire, May suppl 27–33
Social phobia: the consumer's perspective. Ross, Dec suppl 5–9
Specific issues in the cognitive-behavioral treatment of social phobia. Heimberg, Dec suppl 36–45
Therapeutic strategies for the patient with treatment-resistant anxiety. Coplan, May suppl 69–74
Treating anxiety while minimizing abuse and dependence. Sussman, May suppl 44–51
Treatment of anxiety in patients with alcoholism. Frances RJ, May suppl 37–43
Treatment of anxiety in the elderly. Markovitz, May suppl 64–68
Treatment of generalized anxiety disorder in patients with depressive symptomatology. Rickels, Jan suppl 20–23
Utilization of behavioral methods in a multicenter anxiety disorders study. Goisman, June 213–218

Attention-Deficit Hyperactivity Disorder

Attention-deficit hyperactivity disorder and comorbid psychosis: a review and two clinical presentations. Pine, Apr 140–145
Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. Knell, Sept 331–337

Behavior Therapy

Behavior therapy for obsessive compulsive disorder in the office-based practice. Baer, June suppl 10–15
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Hoffart, Dec 481–487
Current issues in the pharmacologic management of obsessive compulsive disorder. Rasmussen SA, June suppl 4–9; Correction, Dec 491
Specific issues in the cognitive-behavioral treatment of social phobia. Heimberg, Dec suppl 36–45
Utilization of behavioral methods in a multicenter anxiety disorders study. Goisman, June 213–218

Benzodiazepines

Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. Cole, Oct suppl 49–61
Alprazolam and benzodiazepine dependence. Sellers, Oct suppl 64–75
Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. Barbee, Oct suppl 86–97
Trazodone in benzodiazepine dependence. Ansseau, May 189–191

Bereavement

Uncomplicated bereavement. Zisook, Oct 365–372

Bipolar Disorder

Effect of valproate on bipolar spectrum temperamental disorders. Deltito, Aug 300–304
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234

Blood Levels

Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Greenblatt, Oct suppl 4–14
Monitoring antidepressant-induced cerebral hyperexcitability [letter]. Forstl; Preskorn reply, May 201–202

Body Dysmorphic Disorder

Body dysmorphic disorder: does it have a psychotic subtype? McElroy, Oct 389–395

Books Reviewed

Ahern FL Jr, Athey JL (eds): *Refugee Children: Theory, Research, and Services*. Arroyo, Mar 117–118
Appelbaum PS, Gutheil TG (eds): *Clinical Handbook of Psychiatry and the Law, 2nd ed.* Tanay, Feb 76
Author as reporter, not advocate [letter]. Esman, July 280
Bauer GP (ed): *Wit and Wisdom in Dynamic Psychotherapy*. Weise, Aug 322
Birkett DP: *Psychiatry in the Nursing Home: Assessment, Evaluation, and Intervention*. Downs, May 203
Birren JE, Sloane RB, Cohen GD (eds): *Handbook of Mental Health and Aging*. Downs, May 203
Campion FX (ed): *Grand Rounds on Medical Malpractice*. Perr, Feb 75
Castelnuovo-Tedesco P: *Dynamic Psychiatry: Explorations in Psychotherapy, Psychoanalysis, and Psychosomatic Medicine*. Jessee, Apr 163–164
Fink PJ, Tasman A (eds): *Stigma and Mental Illness*. Billings, Oct 399
Garza-Treviño ES (ed): *Medical Psychiatry: Theory and Practice*. Ruiz, Apr 164; Correction, June 238
Greenhill LL, Osman BB (eds): *Ritalin: Theory and Patient Management*. Huessy, Mar 117
Hamilton JA, Harberger PN (eds): *Postpartum Psychiatric Illness: A Picture Puzzle*. Surawicz, Aug 322
Johnson KB, Hatlie MJ, Johnson ID: *The Guide to Medical Professional Liability Insurance*. Perr, Feb 74
Joseph AB, Young RR (eds): *Movement Disorders in Psychiatry and Neurology*. Bertorini, Dec 492
Kennedy JA: *Fundamentals of Psychiatric Treatment Planning*. Walker, Nov 443
Kernodle WD: *Panic Disorder:What You Don't Know May Be Dangerous To Your Health*. Patterson, Dec 492
Kerwin R (ed): *Neurobiology and Psychiatry: Volume 1*. Gold Jr, Mar 118
Lamb HR, Bachrach LL, Kass FI (eds): *Treating the Homeless Mentally Ill*. Lunsky, Apr 164
Leenaars AA, Maris RW, McIntosh JL, Richman J (eds): *Suicide and the Older Adult*. Downs, May 203–205
Levenkron S: *Obsessive-Compulsive Disorders: Treating and Understanding Crippling Habits*. Black and Blum, Jan 41
Lindenmayer JP, Kay SR (eds): *New Biological Vistas on Schizophrenia*. Gold Jr, Nov 443
Lynn SJ, Rhue JW (eds): *Theories of Hypnosis: Current Models and Perspectives*. Battle, Apr 163
Marsh DT: *Families and Mental Retardation: New Directions in Professional Practice*. Huessy, Nov 444
Mednick SA, Cannon TD, Barr CE, Lyon M (eds): *Fetal Neural Development and Adult Schizophrenia*. Gold Jr, May 204
Mezey GC, King MB (eds): *Male Victims of Sexual Assault*. Levine, Sept 358
Morse WC (ed): *Crisis Intervention in Residential Treatment: The Clinical Innovations of Fritz Redl*. Stovall, Feb 75–76
Shelby RD: *If a Partner Has AIDS: Guide to Clinical Intervention for Relationships in Crisis*. Allen, July 281
Simon RI (ed): *Review of Clinical Psychiatry and the Law, vol. 3*. Perr, Feb 74–75
Simon RI, Sadoff RL: *Psychiatric Malpractice: Cases and Comments for Clinicians*. Bernet, June 239
Stern EM (ed): *Psychotherapy and the Widowed Patient*. Surawicz, Jan 41
Stoloff ML, Brewster J, Couch JV: *Hardware, Software, and the Mental Health Professional: The Complete Guide to Office Computerization*. Veeser, June 239
Straussner SLA (ed): *Occupational Social Work Today*. Grosso, Sept 358
Weissberg M: *The First Sin of Ross Michael Carlson: A Psychiatrist's Personal Account of Murder, Multiple Personality Disorder and Modern Justice*. Downs, July 281
Yaeger J, Gwirtsman HE, Edelstein CK: *Special Problems in Managing Eating Disorders*. Surawicz, Feb 76

Brain Imaging

Functional brain imaging in late-life depression and dementia. Kumar, Nov suppl 21–25
Magnetic resonance spectroscopy in social phobia: preliminary findings. Davidson, Dec suppl 19–25
Neuroanatomy of depression. Cummings, Nov suppl 14–20
PET and SPECT: opportunities and challenges for psychiatry. Reba, Nov suppl 26–32
Role of nuclear magnetic resonance imaging in psychiatric research. Potts, Dec suppl 13–18
SPECT and PET imaging in mood disorders. George, Nov suppl 6–13
SPECT imaging in psychiatry: introduction and overview. Weinberger, Nov suppl 3–5

Bruxism
SSRI-associated nocturnal bruxism in four patients. Ellison, Nov 432–434
Bupropion
Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient [letter]. Strouse Dec 489–490
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Walker, Dec 459–465
Seizure following bupropion overdose [letter]. Gittelman, Apr 162
Buspirone
Combined carbamazepine-buspirone treatment of alcohol dependence [letter]. de Oliveira, Dec 488
Open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Joffe, July 269–271
Carbamazepine
Combined carbamazepine-buspirone treatment of alcohol dependence [letter]. de Oliveira, Dec 488
Cardiac Arrest
Cardiac arrest during ECT: a cholinergic phenomenon? [letter] Liebowitz NR, July 279–280
Cardiovascular Effects
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Laird, June 224–228
Review of the cardiovascular effects of heterocyclic antidepressants. Glassman, Feb suppl 16–22
Catatonia
Catatonia associated with depression secondary to complex partial epilepsy [letter]. Walls, Feb 73
Ciprofloxacin-induced catatonia [letter]. Akhtar, Mar 115–116
Children
Obsessive compulsive disorder in children and adolescents: issues in management. Rapoport, June suppl 27–29
Psychopharmacologic treatment of anxiety disorders in adolescents and children. Popper, May suppl 52–63
Zinc deficiency and childhood-onset anorexia nervosa. Lask, Feb 63–66
Chronic Fatigue Syndrome
Psychotropic treatment of chronic fatigue syndrome and related disorders. Goodnick, Jan 13–20
Ciprofloxacin
Ciprofloxacin-induced catatonia [letter]. Akhtar, Mar 115–116
Clomipramine
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Hoffart, Dec 481–487
Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. Zohar, Oct 385–388
Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. Hoehn-Saric, July 272–276
Treatment of hypochondriasis with clomipramine [letter]. Stone, May 200–201
Clozapine
Does clozapine cause tardive dyskinesia? Kane, Sept 327–330
Does clozapine cause neuroleptic malignant syndrome? [letter] Weller, Feb 70–71
Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Ratey, June 219–223
High risk of eosinophilia in women treated with clozapine. Banov, Dec 466–469
HLA typing costs [letter]. Landy; Roerig reply, June 236–237
Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. Munn, Nov 439–440
Cognitive Therapy
Specific issues in the cognitive-behavioral treatment of social phobia. Heimberg, Dec suppl 36–45
Combined Drug Therapy
Combined treatment strategies in psychiatry. Nelson, Sept suppl 42–49
Community Care
System approach to reducing relapse in schizophrenia. Stein LI, Mar suppl 7–12
Comorbidity
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Attention-deficit hyperactivity disorder and comorbid psychosis: a review and two clinical presentations. Pine, Apr 140–145
Commentary: sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Vgontzas, July 256–259
Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Wittchen, Jan suppl 9–15
Effects of race and comorbidity on clinical diagnosis in patients with psychosis. Strakowski, Mar 96–102
Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Freeman, May 192–195
How to manage anxious patients who are depressed. Sussman, May suppl 8–16
Introduction. Part I. Treatment strategies for complicated anxiety. Frances AJ, May suppl 3
Introduction. Part II. Treatment strategies for complicated anxiety. Rakel, May suppl 21
Mixed anxiety and depression: should it be included in DSM-IV? Liebowitz MR, May suppl 4–7
Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Nofzinger, July 244–255
Conduct Disorders
Conduct disorder and personality disorders in hospitalized adolescents. Myers, Jan 21–26
Corrections
Basic pharmacokinetic principles and their application to psychotropic drugs. Greenblatt, Sept suppl 8–13; Correction, Nov 442
Comparative pharmacology of new antidepressants. Leonard, Aug suppl 3–15; Correction, Dec 491
Current issues in the pharmacologic management of obsessive compulsive disorder. Rasmussen SA, June suppl 4–9; Correction, Dec 491
Garza-Trevino ES (ed): *Medical Psychiatry: Theory and Practice*. Ruiz, Apr 164; Correction, June 238
Negative symptoms and emotional blunting in schizophrenic patients. de Leon, Mar 103–108; Correction, June 238
Cost and Cost Analysis
Commentary: costs of treating depression. Santiago, Nov 425–426
Economic burden of depression in 1990. Greenberg, Nov 405–418
HLA typing costs [letter]. Landy; Roerig reply, June 236–237
Cough Syrup
Mania and cough syrup [letter]. Clovis; Schadel, May 200
Cyclobenzaprine
Cyclobenzaprine-induced delirium in two octogenarians [letter]. Engel, Jan 39
Cyclothymia
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234
Delinquency
Conduct disorder and personality disorders in hospitalized adolescents. Myers, Jan 21–26
Delirium
Cyclobenzaprine-induced delirium in two octogenarians [letter]. Engel, Jan 39
Dementia
Functional brain imaging in late-life depression and dementia. Kumar, Nov suppl 21–25
Depression
Acute therapy of depression. Bech, Aug suppl 18–27
Alprazolam and depression: a review of risks and benefits. Kravitz, Oct suppl 78–84
d-Amphetamine versus methylphenidate effects in depressed inpatients. Little, Sept 349–355
Approaches to developing new anxiolytics and antidepressants. Dubovsky, May suppl 75–83
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Beyond signs and symptoms: the case against a mixed anxiety and depression category. Preskorn, Jan suppl 24–32
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Laird, June 224–228
Catatonia associated with depression secondary to complex partial epilepsy [letter]. Walls, Feb 73
Commentary: costs of treating depression. Santiago, Nov 425–426
Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Wittchen, Jan suppl 9–15
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45
Depression: a neglected major illness. Greenberg, Nov 419–424
Depression with anxiety and atypical depression. Liebowitz MR, Feb suppl 10–14
Dexamethasone suppression test and onset of poststroke depression in patients with ischemic infarction. Harney, Sept 343–348
Difficult depressed patient in perspective. Keller, Feb suppl 4–8
Economic burden of depression in 1990. Greenberg, Nov 405–418
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Rothschild, Sept 338–342
Electroconvulsive therapy as a treatment for recurrent depression [letter]. Kellner; Thase reply, Nov 441–442

Functional brain imaging in late-life depression and dementia. Kumar, Nov suppl 21–25
Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Freeman, May 192–195
High initial nortriptyline doses in the treatment of depression. Warner, Feb 67–69
How to manage anxious patients who are depressed. Sussman, May suppl 8–16
Introduction. Managing the difficult depressed patient. Keller, Feb suppl 3
Introduction. Part I. Treatment strategies for complicated anxiety. Frances AJ, May suppl 3
Introduction. Part II. Treatment strategies for complicated anxiety. Rakel, May suppl 21
Management of recurrent depression. Kupfer, Feb suppl 29–33
Mixed anxiety and depression: clinical implications. Stahl, Jan suppl 33–38
Mixed anxiety and depression: diagnostic issues. Boulenger, Jan suppl 3–8
Mixed anxiety and depression: should it be included in DSM-IV? Liebowitz MR, May suppl 4–7
Neuroanatomy of depression. Cummings, Nov suppl 14–20
Neurobiological basis of mixed depression-anxiety states. Gulley, Jan suppl 16–19
Open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Joffe, July 269–271
Pharmacologic treatment of depression in the elderly. Salzman, Feb suppl 23–28
Primary care perspective on management of acute and long-term depression. Stokes, Aug suppl 74–84
Psychiatric manifestations of Lyme borreliosis. Fallon, July 263–268
Psychostimulants, poststroke depression, and side effects [letter]. Masand; Lazarus reply, Sept 356
Relationship between depression and length of stay in the general hospital patient. Verbosky, May 177–181
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Maddock, Mar 88–95
Sexual activity among HIV-seropositive gay men seeking treatment for depression. Wagner, Dec 470–475
T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. Dommisse; Cooke reply, July 277–279
Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. Howland, Feb 47–54
Treatment of generalized anxiety disorder in patients with depressive symptomatology. Rickels, Jan suppl 20–23
Uncomplicated bereavement. Zisook, Oct 365–372
Use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. Altamura, Aug suppl 29–37
Use of low-dose fluoxetine in major depression and panic disorder. Louie, Nov 435–438
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar ACADEMIC HIGHLIGHTS 119–126

Dexamethasone Suppression Test
Dexamethasone suppression test and onset of poststroke depression in patients with ischemic infarction. Harney, Sept 343–348

Diagnosis
Beyond signs and symptoms: the case against a mixed anxiety and depression category. Preskorn, Jan suppl 24–32
Body dysmorphic disorder: does it have a psychotic subtype? McElroy, Oct 389–395
Commentary: sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Vgontzas, July 256–259
Diagnostic considerations and treatment approaches to underlying anxiety in the medically ill. Wise, May suppl 22–26
Diagnostic limits of "addiction" [letter]. Satel; Stein DJ reply, June 237–238
Effects of race and comorbidity on clinical diagnosis in patients with psychosis. Strakowski, Mar 96–102
Introduction. Diagnosis and treatment of OCD: a clinician's perspective. Rasmussen SA, June suppl 3
Mixed anxiety and depression: diagnostic issues. Boulenger, Jan suppl 3–8
Mixed anxiety and depression: should it be included in DSM-IV? Liebowitz MR, May suppl 4–7
Obsessive compulsive disorder with psychotic features. Eisen, Oct 373–379
Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Hughes, Mar 109–114
Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Nofzinger, July 244–255
Uncomplicated bereavement. Zisook, Oct 365–372

Discrimination
Mental health care policy in the 1990s: discrimination in health care coverage of the seriously mentally ill. Domenici PV, Mar suppl 5–6

Divalproex Sodium
Divalproex sodium in the treatment of refractory affective disorders. Schaff, Oct 380–384

Dose
Dose response of prophylactic antipsychotics. Davis, Mar suppl 24–30
High initial nortriptyline doses in the treatment of depression. Warner, Feb 67–69
Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. Heresco-Levy, Feb 59–62
Valproate oral loading in the treatment of acute mania. Keck Jr, Aug 305–308

Drug Administration Schedule
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf, Jan 33–38

Drug Abuse see Substance Abuse

Drug Dependence/Withdrawal
Alprazolam and benzodiazepine dependence. Sellers, Oct suppl 64–75
Trazodone in benzodiazepine dependence. Ansseau, May 189–191
Treating anxiety while minimizing abuse and dependence. Sussman, May suppl 44–51

Drug Discontinuation
Abrupt discontinuation of fluvoxamine in patients with panic disorder. Black, Apr 146–149
Antidepressant maintenance medications: when to discontinue and how to stop. Greden, Aug suppl 39–45
Medication discontinuation in panic disorder. Ballenger, Oct suppl 15–21

Drug Interactions
Adverse drug reactions/interactions in maintenance therapy. Tollefson, Aug suppl 48–58
MAOI-narcotic interactions [letter]. Gratz, Nov 439

Drug Side Effects
Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient [letter]. Strouse Dec 489–490
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202
Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. Cole, Oct suppl 49–61
Akathisia and sertraline [letter]. Settle Jr, Aug 321
Akathisia as EPS [letter]. Pearlman; Opler reply, July 280
Cyclobenzaprine-induced delirium in two octogenarians [letter]. Engel, Jan 39
Molindone and weight loss [letter]. Heikkinen, Apr 160–161
Monitoring antidepressant-induced cerebral hyperexcitability [letter]. Forstl; Preskorn reply, May 201–202
Psychostimulants, poststroke depression, and side effects [letter]. Masand; Lazarus reply, Sept 356
Seizure following bupropion overdose [letter]. Gittelman, Apr 162
Vasoconstrictive effects and SSRIs [letter]. Fricchione; Spier reply, Feb 71–72

Drug Therapy
Management of recurrent depression. Kupfer, Feb suppl 29–33
Pharmacotherapy of social phobia. Liebowitz MR, Dec suppl 31–35
Pharmacologic treatment of depression in the elderly. Salzman, Feb suppl 23–28
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Maddock, Mar 88–95

DSM-III-R see Diagnosis

Eating Disorders
Zinc deficiency and childhood-onset anorexia nervosa. Lask, Feb 63–66

Education
Role of family education. Domenici N, Mar suppl 31–34

Electroconvulsive Therapy
Biological approaches to treatment-resistant obsessive compulsive disorder. Goodman, June suppl 16–26
Cardiac arrest during ECT: a cholinergic phenomenon? [letter] Liebowitz NR, July 279–280
Electroconvulsive therapy as a treatment for recurrent depression [letter]. Kellner; Thase reply, Nov 441–442
Electroconvulsive therapy in patients taking theophylline. Rasmussen KG, Nov 427–431

Electroencephalography
EEG in psychiatry [letter]. Serafetinides, Oct 397

Environmental Exposure
Successful management of patients with "multiple chemical sensitivities" on an inpatient psychiatric unit. Haller, May 196–199

Eosinophilia
High risk of eosinophilia in women treated with clozapine. Banov, Dec 466–469

Epidemiology
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Wittchen, Jan suppl 9–15
Epilepsy
Catatonia associated with depression secondary to complex partial epilepsy [letter]. Walls, Feb 73
Extrapyramidal Side Effects
Akathisia as EPS [letter]. Pearlman; Opler reply, July 280
Family
Role of family education. Domenici N, Mar suppl 31–34
Fibromyalgia
Psychotropic treatment of chronic fatigue syndrome and related disorders. Goodnick, Jan 13–20
Fluoxetine
Association of fluoxetine and return of sexual potency in three elderly men. Smith DM, Aug 317–319
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Rothschild, Sept 338–342
Fluoxetine efficacy in social phobia. Van Ameringen, Jan 27–32
Fluoxetine-induced sexual dysfunction [letter]. Patterson, Feb 71
Fluoxetine-induced sexual dysfunction and yohimbine [letter]. Balon; Jacobsen reply, Apr 161–162
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Walker, Dec 459–465
Migraine with typical aura associated with fluoxetine therapy: case report [letter]. Larson, June 235–236
Titration of serotonin reuptake blockers [letter]. Terao; Balogh reply; Hollander reply, Mar 115
Use of low-dose fluoxetine in major depression and panic disorder. Louie, Nov 435–438
Fluvoxamine
Abrupt discontinuation of fluvoxamine in patients with panic disorder. Black, Apr 146–149
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Laird, June 224–228
Freedman, Daniel X. (1921–1993).
In memoriam. Baxter, Oct 363–364
Fregoli Syndrome
Fregoli syndrome with a jealous theme [letter]. Sanati, Dec 490–491
Generalized Anxiety Disorder see Anxiety
Genetics
Heritability of social anxiety: a brief review. Fyer, Dec suppl 10–12
Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. Knell, Sept 331–337
Geriatric Psychiatry
Association of fluoxetine and return of sexual potency in three elderly men. Smith DM, Aug 317–319
Clinical characteristics of panic disorder in the elderly: a retrospective study. Raj, Apr 150–155
Cyclobenzaprine-induced delirium in two octogenarians [letter]. Engel, Jan 39
Functional brain imaging in late-life depression and dementia. Kumar, Nov suppl 21–25
Pharmacologic treatment of depression in the elderly. Salzman, Feb suppl 23–28
Psychopharmacologic treatment of anxiety in the medically ill elderly patient: special considerations. Stoudemire, May suppl 27–33
Treatment of anxiety in the elderly. Markovitz, May suppl 64–68
Gilles de la Tourette's Disease see Tourette's Syndrome
Gonadotropin-Releasing Hormone
Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Freeman, May 192–195
Health Care Policy
Mental health care policy in the 1990s: discrimination in health care coverage of the seriously mentally ill. Domenici PV, Mar suppl 5–6
Role of family education. Domenici N, Mar suppl 31–34
Heredity see Genetics
HLA Typing
HLA typing costs [letter]. Landy; Roerig reply, June 236–237
Homeless Persons
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Homosexuality
Adventitious change in homosexual behavior during treatment of social phobia with phenelzine [letter]. Golwyn, Jan 39–40
Hospitalization
Relationship between depression and length of stay in the general hospital patient. Verbosky, May 177–181
Human Immunodeficiency Virus
Sexual activity among HIV-seropositive gay men seeking treatment for depression. Wagner, Dec 470–475
Hypnotics
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf, Jan 33–38
Hypochondriasis
Treatment of hypochondriasis with clomipramine [letter]. Stone, May 200–201
Hyponatremia
Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. Munn, Nov 439–440
Hypothalamic-Pituitary-Thyroid Axis
Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. Howland, Feb 47–54
Hypothyroidism
T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. Dommisse; Cooke reply, July 277–279
Imipramine
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Laird, June 224–228
In Memoriam
Freedman, Daniel X. (1921–1993). Baxter, Oct 363–364
Van Putten, Theodore (1938–1993). Gelenberg, July 243
Inpatients
Nadolol in the treatment of aggression in chronic psychiatric inpatients [letter]. Wong, June 235
Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Hughes, Mar 109–114
Successful management of patients with "multiple chemical sensitivities" on an inpatient psychiatric unit. Haller, May 196–199
Insomnia see also Sleep Disorders
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf, Jan 33–38
Iron
Iron for akathisia and persistent akathisia? [letter] Chengappa, Aug 320–321
Journal of Clinical Psychiatry
Author as reporter, not advocate [letter]. Esman, July 280
Literature of clinical psychiatry [editorial]. Gelenberg, Mar 81
New Year's Gratitude [editorial]. Gelenberg, Dec 457–458
Psychiatry 2013 [editorial]. Gelenberg, Aug 287–288
Lithium
Converting from Lithobid to other lithium preparations [letter]. Jefferson, Oct 396–397
Prospective clinical evaluation of an equation to predict daily lithium dose. Cummings, Feb 55–58
Liver Transplantation
Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient [letter]. Strouse Dec 489–490
Lyme Borreliosis
Psychiatric manifestations of Lyme borreliosis. Fallon, July 263–268
Magnetic Resonance Imaging
Magnetic resonance spectroscopy in social phobia: preliminary findings. Davidson, Dec suppl 19–25
Role of nuclear magnetic resonance imaging in psychiatric research. Potts, Dec suppl 13–18
Magnetic Resonance Spectroscopy
Magnetic resonance spectroscopy in social phobia: preliminary findings. Davidson, Dec suppl 19–25
Role of nuclear magnetic resonance imaging in psychiatric research. Potts, Dec suppl 13–18
Maintenance Treatment
Adverse drug reactions/interactions in maintenance therapy. Tollefson, Aug suppl 48–58
Antidepressant maintenance medications: when to discontinue and how to stop. Greden, Aug suppl 39–45
Major Depression see Depression
Mania
Mania and cough syrup [letter]. Clovis; Schadel, May 200
Psychiatric manifestations of Lyme borreliosis. Fallon, July 263–268
Valproate oral loading in the treatment of acute mania. Keck Jr, Aug 305–308
Medical Illness
Diagnostic considerations and treatment approaches to underlying anxiety in the medically ill. Wise, May suppl 22–26
Introduction. Part II. Treatment strategies for complicated anxiety. Rakel, May suppl 21

Psychopharmacologic treatment of anxiety in the medically ill elderly patient: special considerations. Stoudemire, May suppl 27–33
Relationship between depression and length of stay in the general hospital patient. Verbosky, May 177–181
Medroxyprogesterone Acetate
Low-dose oral medroxyprogesterone acetate in the management of the paraphilias. Gottesman, May 182–188
Memory
Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. Barbee, Oct suppl 86–97
Menstrual Cycle
Case of phenobarbital behavioral toxicity presenting as a menstrually-related mood disorder [letter]. Campbell, Nov 441
Mental Health
Discussant Section. Psychotic relapse. England, Mar suppl 35–36
Mental health care policy in the 1990s: discrimination in health care coverage of the seriously mentally ill. Domenici PV, Mar suppl 5–6
Role of family education. Domenici N, Mar suppl 31–34
Meta-Analysis
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Metabolism
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Greenblatt, Oct suppl 4–14
Pharmacokinetics of psychotropic drugs in special populations. Rudorfer, Sept suppl 50–54
Methylphenidate
d-Amphetamine versus methylphenidate effects in depressed inpatients. Little, Sept 349–355
Migraine
Migraine with typical aura associated with fluoxetine therapy: case report [letter]. Larson, June 235–236
Moclobemide
New antidepressants: use in high-risk patients. Hale, Aug suppl 61–70
Molindone
Molindone and weight loss [letter]. Heikkinen, Apr 160–161
Monoamine Oxidase Inhibitors
MAOI-narcotic interactions [letter]. Gratz, Nov 439
Mood
Case of phenobarbital behavioral toxicity presenting as a menstrually-related mood disorder [letter]. Campbell, Nov 441
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41
SPECT and PET imaging in mood disorders. George, Nov suppl 6–13
Multiple Chemical Sensitivities
Successful management of patients with "multiple chemical sensitivities" on an inpatient psychiatric unit. Haller, May 196–199
Nadolol
Nadolol in the treatment of aggression in chronic psychiatric inpatients [letter]. Wong, June 235
Narcotics
MAOI-narcotic interactions [letter]. Gratz, Nov 439
Negative Symptoms
Negative symptoms and emotional blunting in schizophrenic patients. de Leon, Mar 103–108; Correction, June 238
Neuroanatomy
Neuroanatomy of depression. Cummings, Nov suppl 14–20
Neurobiology
Neurobiological basis of mixed depression-anxiety states. Gulley, Jan suppl 16–19
Neurobiology of social phobia. Tancer, Dec suppl 26–30
Neuroleptic Drugs
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Glazer, Apr 133–139
Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. Heresco-Levy, Feb 59–62
Neuroleptic-Induced Deficit Syndrome (NIDS)
Neuroleptic-induced deficit syndrome (NIDS). Dec ACADEMIC HIGHLIGHTS 493–500
Neuroleptic Malignant Syndrome
Does clozapine cause neuroleptic malignant syndrome? [letter] Weller, Feb 70–71
Nortriptyline
High initial nortriptyline doses in the treatment of depression. Warner, Feb 67–69
Obsessive Compulsive Disorder
Behavior therapy for obsessive compulsive disorder in the office-based practice. Baer, June suppl 10–15
Biological approaches to treatment-resistant obsessive compulsive disorder. Goodman, June suppl 16–26
Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. Zohar, Oct 385–388
Current issues in the pharmacologic management of obsessive compulsive disorder. Rasmussen SA, June suppl 4–9; Correction, Dec 491
Introduction. Diagnosis and treatment of OCD: a clinician's perspective. Rasmussen SA, June suppl 3
Obsessive compulsive disorder in children and adolescents: issues in management. Rapoport, June suppl 27–29
Obsessive compulsive disorder manifesting as demonic attack [letter]. Lacy, Oct 398
Obsessive compulsive disorder with psychotic features. Eisen, Oct 373–379
Postpartum obsessive compulsive disorder: a case series. Sichel, Apr 156–159
Slow eating: OCD or simple phobia? [letter] Balon; Galynker reply, Nov 440–441
Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. Hoehn-Saric, July 272–276
Organic Mental Disorders
Case of organic Othello syndrome [letter]. Silva, July 277
Othello Syndrome
Case of organic Othello syndrome [letter]. Silva, July 277
Outcome
Prediction of outcome in first-episode schizophrenia. Lieberman, Mar suppl 13–17
Outpatients
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Laird, June 224–228
Over-the-Counter Drugs
Mania and cough syrup [letter]. Clovis; Schadel, May 200
Panic
Abrupt discontinuation of fluvoxamine in patients with panic disorder. Black, Apr 146–149
Clinical characteristics of panic disorder in the elderly: a retrospective study. Raj, Apr 150–155
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Hoffart, Dec 481–487
Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas, Oct suppl 25–45
Medication discontinuation in panic disorder. Ballenger, Oct suppl 15–21
Paniclike symptoms after veralipride withdrawal [letter]. Iruela, Dec 488–489
Postpartum onset of panic disorder: a coincidental event? Sholomskas, Dec 476–480
Psychiatric manifestations of Lyme borreliosis. Fallon, July 263–268
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Maddock, Mar 88–95
Use of low-dose fluoxetine in major depression and panic disorder. Louie, Nov 435–438
Paraphilias
Low-dose oral medroxyprogesterone acetate in the management of the paraphilias. Gottesman, May 182–188
Perphenazine
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Rothschild, Sept 338–342
Personality Disorders
Conduct disorder and personality disorders in hospitalized adolescents. Myers, Jan 21–26
Pharmacokinetics
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Greenblatt, Oct suppl 4–14
Basic pharmacokinetic principles and their application to psychotropic drugs. Greenblatt, Sept suppl 8–13; Correction, Nov 442
Combined treatment strategies in psychiatry. Nelson, Sept suppl 42–49
Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. Preskorn, Sept suppl 3–7
Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Preskorn, Sept suppl 14–34
Pharmacokinetics of psychotropic drugs in special populations. Rudorfer, Sept suppl 50–54
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41
Pharmacology
Comparative pharmacology of new antidepressants. Leonard, Aug suppl 3–15
Pharmacotherapy
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Goldstein, Aug 309–316
Approaches to developing new anxiolytics and antidepressants. Dubovsky, May suppl 75–83
Current issues in the pharmacologic management of obsessive compulsive disorder. Rasmussen SA, June suppl 4–9; Correction, Dec 491

Pharmacotherapy of social phobia. Liebowitz MR, Dec suppl 31–35
Therapeutic strategies for the patient with treatment-resistant anxiety. Coplan, May suppl 69–74
Phenelzine
Adventitious change in homosexual behavior during treatment of social phobia with phenelzine [letter]. Golwyn, Jan 39–40
Phenobarbital
Case of phenobarbital behavioral toxicity presenting as a menstrually-related mood disorder [letter]. Campbell, Nov 441
Phobias
Adventitious change in homosexual behavior during treatment of social phobia with phenelzine [letter]. Golwyn, Jan 39–40
Fluoxetine efficacy in social phobia. Van Ameringen, Jan 27–32
Heritability of social anxiety: a brief review. Fyer, Dec suppl 10–12
Introduction. Social phobia in review: 1993. Davidson, Dec suppl 3–4
Magnetic resonance spectroscopy in social phobia: preliminary findings. Davidson, Dec suppl 19–25
Neurobiology of social phobia. Tancer, Dec suppl 26–30
Pharmacotherapy of social phobia. Liebowitz MR, Dec suppl 31–35
Role of nuclear magnetic resonance imaging in psychiatric research. Potts, Dec suppl 13–18
Slow eating: OCD or simple phobia? [letter] Balon; Galynker reply, Nov 440–441
Social phobia: an overview of treatment strategies. Apr ACADEMIC HIGHLIGHTS 165–171
Social phobia: the consumer's perspective. Ross, Dec suppl 5–9
Specific issues in the cognitive-behavioral treatment of social phobia. Heimberg, Dec suppl 36–45
Polydipsia
Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. Munn, Nov 439–440
Positron Emission Tomography
PET and SPECT: opportunities and challenges for psychiatry. Reba, Nov suppl 26–32
SPECT and PET imaging in mood disorders. George, Nov suppl 6–13
Postpartum
Postpartum obsessive compulsive disorder: a case series. Sichel, Apr 156–159
Postpartum onset of panic disorder: a coincidental event? Sholomskas, Dec 476–480
Prediction
Prospective clinical evaluation of an equation to predict daily lithium dose. Cummings, Feb 55–58
Premenstrual Syndrome
Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Freeman, May 192–195
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234
Prescriptions, Drug
More on nonphysician prescribers [letter]. Skowron; Sovner reply, Oct 396
Primary Care
Primary care perspective on management of acute and long-term depression. Stokes, Aug suppl 74–84
Psychiatry
Combined treatment strategies in psychiatry. Nelson, Sept suppl 42–49
Literature of clinical psychiatry [editorial]. Gelenberg, Mar 81
Psychiatry 2013 [editorial]. Gelenberg, Aug 287–288
EEG in psychiatry [letter]. Serafetinides, Oct 397
SPECT imaging in psychiatry: introduction and overview. Weinberger, Nov suppl 3–5
Psychosis
Attention-deficit hyperactivity disorder and comorbid psychosis: a review and two clinical presentations. Pine, Apr 140–145
Body dysmorphic disorder: does it have a psychotic subtype? McElroy, Oct 389-395
Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Ratey, June 219–223
Effects of race and comorbidity on clinical diagnosis in patients with psychosis. Strakowski, Mar 96–102
Obsessive compulsive disorder with psychotic features. Eisen, Oct 373–379
Understanding and treating psychoses: advances in research and therapy. Nov ACADEMIC HIGHLIGHTS 445–452
Psychostimulants
Psychostimulants, poststroke depression, and side effects [letter]. Masand; Lazarus reply, Sept 356
Psychosurgery
Biological approaches to treatment-resistant obsessive compulsive disorder. Goodman, June suppl 16–26
Psychotherapy
Specific issues in the cognitive-behavioral treatment of social phobia. Heimberg, Dec suppl 36–45
Therapeutic strategies for the patient with treatment-resistant anxiety. Coplan, May suppl 69–74
Psychotropic Drugs
Basic pharmacokinetic principles and their application to psychotropic drugs. Greenblatt, Sept suppl 8–13; Correction, Nov 442
Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. Preskorn, Sept suppl 3–7
Pharmacokinetics of psychotropic drugs in special populations. Rudorfer, Sept suppl 50–54
Psychopharmacologic screening criteria [letter]. Peterson; Kane reply, Oct 397–398
Psychotropic treatment of chronic fatigue syndrome and related disorders. Goodnick, Jan 13–20
Quazepam
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf, Jan 33–38
Race
Effects of race and comorbidity on clinical diagnosis in patients with psychosis. Strakowski, Mar 96–102
Rapid Cycling
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234
Relapse
Introduction. Psychotic relapse: a multisystems perspective. Glazer, Mar suppl 3–4
Prevention of relapse in chronic schizophrenic patients. Hogarty, Mar suppl 18–23
System approach to reducing relapse in schizophrenia. Stein LI, Mar suppl 7–12
Religion
Obsessive compulsive disorder manifesting as demonic attack [letter]. Lacy, Oct 398
Rib Fractures
Rib fractures as an unusual complication of severe tardive dystonia [letter]. Szymanski, Apr 160
Schizophrenia
Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. Zohar, Oct 385–388
Contribution of anticholinergic medication to symptom change in schizophrenia [letter]. DeQuardo; Serban reply, Sept 356–357
Dose response of prophylactic antipsychotics. Davis, Mar suppl 24–30
Introduction. Psychotic relapse: a multisystems perspective. Glazer, Mar suppl 3–4
Negative symptoms and emotional blunting in schizophrenic patients. de Leon, Mar 103–108; Correction, June 238
Prediction of outcome in first-episode schizophrenia. Lieberman, Mar suppl 13–17
Prevention of relapse in chronic schizophrenic patients. Hogarty, Mar suppl 18–23
Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. Munn, Nov 439–440
System approach to reducing relapse in schizophrenia. Stein LI, Mar suppl 7–12
Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. Heresco-Levy, Feb 59–62
Seasons
Preliminary data on seasonally related alcohol dependence. McGrath, July 260–262
Seizures
Advancing age may inhibit antidepressant-induced seizure [letter]. Swartz, May 202
Monitoring antidepressant-induced cerebral hyperexcitability [letter]. Forstl; Preskorn reply, May 201–202
Seizure following bupropion overdose [letter]. Gittelman, Apr 162
Seizures associated with antidepressants: a review. Rosenstein, Aug 289–299
Serotonin Reuptake Inhibitors
Comparative pharmacology of new antidepressants. Leonard, Aug suppl 3–15; Correction, Dec 491
Introduction. Diagnosis and treatment of OCD: a clinician's perspective. Rasmussen SA, June suppl 3
Open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Joffe, July 269–271
SSRI-associated nocturnal bruxism in four patients. Ellison, Nov 432–434
Titration of serotonin reuptake blockers [letter]. Terao; Balogh reply; Hollander reply, Mar 115
Vasoconstrictive effects and SSRIs [letter]. Fricchione; Spier reply, Feb 71–72
Sertraline
Akathisia and sertraline [letter]. Settle Jr, Aug 321
Sexual Behavior
Sexual activity among HIV-seropositive gay men seeking treatment for depression. Wagner, Dec 470–475

Sexual Disorders see also Paraphilias
Diagnostic limits of "addiction" [letter]. Satel; Stein DJ reply, June 237–238
Low-dose oral medroxyprogesterone acetate in the management of the paraphilias. Gottesman, May 182–188
Sexual Dysfunction
Association of fluoxetine and return of sexual potency in three elderly men. Smith DM, Aug 317–319
Fluoxetine-induced sexual dysfunction and yohimbine [letter]. Balon; Jacobsen reply, Apr 161–162
Fluoxetine-induced sexual dysfunction [letter]. Patterson, Feb 71
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Walker, Dec 459–465
Sexual dysfunction during antidepressant treatment. Balon, June 209–212
Single Photon Emission Computed Tomography
PET and SPECT: opportunities and challenges for psychiatry. Reba, Nov suppl 26–32
SPECT and PET imaging in mood disorders. George, Nov suppl 6–13
SPECT imaging in psychiatry: introduction and overview. Weinberger, Nov suppl 3–5
Sleep Disorders
Commentary: sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Vgontzas, July 256–259
Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. Nofzinger, July 244–255
Smoking
Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Hughes, Mar 109–114
Social Phobia see Phobias
Somatization Disorder
Successful management of patients with "multiple chemical sensitivities" on an inpatient psychiatric unit. Haller, May 196–199
Stroke
Dexamethasone suppression test and onset of poststroke depression in patients with ischemic infarction. Harney, Sept 343–348
Psychostimulants, poststroke depression, and side effects [letter]. Masand; Lazarus reply, Sept 356
Substance Abuse
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Mania and cough syrup [letter]. Clovis; Schadel, May 200
Treating anxiety while minimizing abuse and dependence. Sussman, May suppl 44–51
Treatment of anxiety in patients with alcoholism. Frances RJ, May suppl 37–43
Suicide
Akathisia and sertraline [letter]. Settle Jr, Aug 321
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Goldstein, Aug 309–316
Tardive Dyskinesia
Does clozapine cause tardive dyskinesia? Kane, Sept 327–330
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Glazer, Apr 133–139
Rib fractures as an unusual complication of severe tardive dystonia [letter]. Szymanski, Apr 160
Tardive Dystonia
Rib fractures as an unusual complication of severe tardive dystonia [letter]. Szymanski, Apr 160
Theophylline
Electroconvulsive therapy in patients taking theophylline. Rasmussen KG, Nov 427–431
Therapeutic Drug Monitoring
Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Janicak, Sept suppl 35–41
Thyroid Function
T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. Dommisse; Cooke reply, July 277–279
Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. Howland, Feb 47–54
Thyroxine
T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. Dommisse; Cooke reply, July 277–279
Tourette's Syndrome
Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. Knell, Sept 331–337
Toxicity
Case of phenobarbital behavioral toxicity presenting as a menstrually-related mood disorder [letter]. Campbell, Nov 441
Trazodone
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Workman, Jan 5–12
Trazodone in benzodiazepine dependence. Ansseau, May 189–191
Triazolam
Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Scharf, Jan 33–38
Trichotillomania
Prevalence of trichotillomania in a college freshman population [letter]. Rothbaum; Christenson reply, Feb 72–73
Triiodothyronine
T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. Dommisse; Cooke reply, July 277–279
Unipolar Disorder see Depression
Valproate
Effect of valproate on bipolar spectrum temperamental disorders. Deltito, Aug 300–304
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234
Valproate oral loading in the treatment of acute mania. Keck Jr, Aug 305–308
Van Putten, Theodore (1938–1993).
In memoriam. Gelenberg, July 243
Venlafaxine
Venlafaxine: a new dimension in antidepressant pharmacotherapy. Mar ACADEMIC HIGHLIGHTS 119–126
Veralipride
Paniclike symptoms after veralipride withdrawal [letter]. Iruela, Dec 488–489
Violence
Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Ratey, June 219–223
Weight
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Goldstein, Aug 309–316
Molindone and weight loss [letter]. Heikkinen, Apr 160–161
Women
Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Smith EM, Mar 82–87
Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Freeman, May 192–195
High risk of eosinophilia in women treated with clozapine. Banov, Dec 466–469
Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Jacobsen, June 229–234
Postpartum obsessive compulsive disorder: a case series. Sichel, Apr 156–159
Postpartum onset of panic disorder: a coincidental event? Sholomskas, Dec 476–480
Yohimbine
Fluoxetine-induced sexual dysfunction and yohimbine [letter]. Balon; Jacobsen reply, Apr 161–162
Titration of serotonin reuptake blockers [letter]. Terao; Balogh reply; Hollander reply, Mar 115
Zinc
Zinc deficiency and childhood-onset anorexia nervosa. Lask, Feb 63–66

Journal of Clinical Psychiatry

Author Index to Volume 54: January 1993 Through December 1993

Ahmad H see Akhtar S

Akhtar S, Ahmad H. Ciprofloxacin-induced catatonia [letter]. Mar 115–116

Albert J see Freeman EW

Allen DM. Review of Shelby RD: *If a Partner Has AIDS: Guide to Clinical Intervention for Relationships in Crisis*. July 281

Altamura AC, Percudani M. Use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions. Aug suppl 29–37

Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. May 189–191

Aronson SC see Goodman WK

Arroyo W. Review of Ahern FL Jr, Athey JL (eds): *Refugee Children: Theory, Research, and Services*. Mar 117–118

Baer L. Behavior therapy for obsessive compulsive disorder in the office-based practice. June suppl 10–15

Bailey KP see Sovner R

Baird J see Chengappa KNR

Baker RW see Chengappa KNR

Ballenger JC. Overview: issues in the clinical use of alprazolam. Oct suppl 3

Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. Oct suppl 15–21

Ballenger JC see Laird LK

Balogh S, Hendricks SE. Reply to Terao T: Titration of serotonin reuptake blockers [letter]. Mar 115

Balon R. Fluoxetine-induced sexual dysfunction and yohimbine [letter with reply]. Apr 161

Balon R. Slow eating: OCD or simple phobia? [letter with reply]. Nov 440–441

Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. June 209–212

Banov M, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. Dec 466–469

Barbee JG. Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. Oct suppl 86–97

Barr LC see Goodman WK

Batey SR see Walker PW

Battle AO. Review of Lynn SJ, Rhue JW (eds): *Theories of Hypnosis: Current Models and Perspectives*. Apr 163

Baxter LR, Reiman EM. In memoriam: Daniel X. Freedman, M.D. Oct 363–364

Beale MD see Kellner CH

Beasley CM Jr see Goldstein DJ

Bech P. Acute therapy of depression. Aug suppl 18–27

Beitman BD see Maddock RJ

Benjamin J see Zohar J

Bennett JA see Keck PE Jr

Berndt ER see Greenberg PE

Bernet W. Review of Simon RI, Sadoff RL: *Psychiatric Malpractice: Cases and Comments for Clinicians*. June 239

Bertorini TE. Review of Joseph AB, Young RR, *Movement Disorders in Psychiatry and Neurology*. Dec 492

Bessette MP see Rothschild AJ

Bille H see Hoffart A

Billings CK. Review of Fink PJ, Tasman A (eds): *Stigma and Mental Illness*. Oct 399

Bixler EO see Vgontzas AN

Black DW, Blum NS. Review of Levenkron S: *Obsessive-Compulsive Disorders: Treating and Understanding Crippling Habits*. Jan 41

Black DW, Wesner R, Gabel J. Abrupt discontinuation of fluvoxamine in patients with panic disorder. Apr 146–149

Blacker KH see Maddock RJ

Blum NS see Black DW

Borg L see Frances RJ

Boulenger J-P, Lavallee Y-J. Mixed anxiety and depression: diagnostic issues. Jan suppl 3–8

Bowers TC see Walls MJ

Boyko O see Davidson JRT

Brauzer B see Davis JM

Brown WA see Heresco-Levy U

Burket RC see Myers WC

Buysse DJ see Nofzinger EA

Caballero L see Iruela LM

Campbell JJ, McNamara ME. Case of phenobarbital behavioral toxicity presenting as a menstrually related mood disorder [letter]. Nov 441

Carter CS see Maddock RJ

Carter-Campbell JT see Rothschild AJ

Casey DE see Davis JM

Chapron D see Engel PA

Charles HC see Davidson JRT

Chengappa KNR, Baker RW, Baird J. Iron for akathisia and persistent akathisia? [letter] Aug 320–321

Christenson GA, Pyle RL, Mitchell JE. Reply to Rothbaum BO: Prevalence of trichotillomania in a college freshman population [letter]. Feb 73

Ciraulo DA see Greenblatt DJ; Sellers EM

Clovis WL. Mania and cough syrup [letter]. May 200

Cohen LS see Sichel DA

Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. Oct suppl 49–61

Cole JO see Walker PW

Comings DE see Knell ER

Cohon MS see Jonas JM

Cooke RG, Joffe RT, Levitt AJ. Reply to Dommisse J: T_3 is at least as important as T_4 in *all* hypothyroid patients [letter]. July 278–279

Coplan JD, Tiffon L, Gorman JM. Therapeutic strategies for the patient with treatment-resistant anxiety. May suppl 69–74

Corvea MH see Raj BA

Cuesta MJ see de Leon J

Cummings JL. Neuroanatomy of depression. Nov suppl 14–20

Cummings MA, Haviland MG, Wareham JG, Fontana LA. Prospective clinical evaluation of an equation to predict daily lithium dose. Feb 55–58

Cuneo P see Goisman RM

Dagon EM see Raj BA

da Rocha FP see de Oliveira IR

Dasberg H see Heresco-Levy U

Davidson JRT. Introduction. Social phobia in review: 1993. Dec suppl 3–4

Davidson JRT, Krishnan KRR, Charles HC, Boyko O, Potts NLS, Ford SM, Patterson L. Magnetic resonance spectroscopy in social phobia: preliminary findings. Dec suppl 19–25

Davidson JRT see Potts NLS

Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M. Dose response of prophylactic antipsychotics. Mar suppl 24–30

de A Miranda A see de Oliveira IR

de Leon J, Peralta V, Cuesta MJ. Negative symptoms and emotional blunting in schizophrenic patients. Mar 103–108. Correction, June 238

de Oliveira IR, da Rocha FP, Pereira EL, de A Miranda A, Ribeiro MG, Melo A. Combined carbamazepine-buspirone treatment of alcohol dependence [letter]. Dec 488

De Roeck J see Ansseau M

Deltito JA. Effect of valproate on bipolar spectrum temperamental disorders. Aug 300–304

DeQuardo JR, Kloss RJ. Contribution of anticholinergic medication to symptom change in schizophrenia [letter with reply]. Sept 356–357

Dilsaver SC see Walls MJ

Dimmock JA see Sichel DA

Dogolo L see Sholomskas DE

Domenici N, Griffin-Francell C. Role of family education. Mar suppl 31–34

Domenici PV. Mental health care policy in the 1990s: discrimination in health care coverage of the seriously mentally ill. Mar suppl 5–6

Dommisse J. T_3 is at least as important as T_4 in *all* hypothyroid patients [letter with reply]. July 277–278

Doucette JT see Glazer WM

Downs JM. Review of Birkett DP: *Psychiatry in the Nursing Home: Assessment, Evaluation, and Intervention.* May 203

Downs JM. Review of Birren JE, Sloane RB, Cohen GD (eds): *Handbook of Mental Health and Aging, 2nd ed.* May 203

Downs JM. Review of Leenaars AA, Maris RW, McIntosh JL, Richman J (eds): *Suicide and the Older Adult.* May 203–204

Downs JM, Goodman E. Review of Weissberg M: *The First Sin of Ross Michael Carlson: A Psychiatrist's Personal Account of Murder, Multiple Personality Disorder and Modern Justice.* July 281

Dubovsky SL. Approaches to developing new anxiolytics and antidepressants. May suppl 75–83

Due-Madsen J see Hoffart A

DuPont RL see Sellers EM

Eisen JL, Rasmussen SA. Obsessive compulsive disorder with psychotic features. Oct 373–379

Eisen JL see Rasmussen SA

El-Mallakh RS see Liebowitz NR

Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. Nov 432–434

Engel PA, Chapron D. Cyclobenzaprine-induced delirium in two octogenarians [letter]. Jan 39

England MJR. Discussant section. Mar suppl 35–36

Esman AH. Author as reporter, not advocate [letter]. July 280

Essau CA see Wittchen H-U

Fallon BA, Nields JA, Parsons B, Liebowitz MR, Klein DF. Psychiatric manifestations of Lyme borreliosis. July 263–268

Fast GA see Preskorn SH

Fawcett J see Kravitz HM; Schaff MR

Finkelstein SN see Greenberg PE

Fontana LA see Cummings MA

Ford SM see Davidson JRT

Forstl H, Pohlmann-Eden B. Monitoring antidepressant-induced cerebral hyperexcitability [letter with reply]. May 201

Fosson A see Lask B

Frances AJ. Introduction. Part I. Treatment strategies for complicated anxiety. May suppl 3

Frances RJ, Borg L. Treatment of anxiety in patients with alcoholism. May suppl 37–43

Franco KN see Verbosky LA

Freeman EW, Sondheimer SJ, Rickels K, Albert J. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. May 192–195

Fricchione GL, Woznicki RM, Klesmer J, Vlay SC. Vasoconstrictive effects and SSRIs [letter with reply]. Feb 71–72

Friedberg J see Banov MD

Frontera MA see Spier SA

Fulton C see Harney JH

Fyer AJ. Heritability of social anxiety: a brief review. Dec suppl 10–12

Gabel J see Black DW

Galkowski B see Szymanski S

Galynker I, Kahn RS. Reply to Balon R: Slow eating: OCD or simple phobia? [letter] Nov 440–441

Gardner EA see Walker PW

Gelenberg AJ. In Memoriam: Theodore Van Putten, M.D. July 243

Gelenberg AJ. Literature of clinical psychiatry [editorial]. Mar 81

Gelenberg AJ. New Year's gratitude [editorial]. Dec457–458

Gelenberg AJ. Psychiatry 2013 [editorial]. Aug 287–288

George MS, Ketter TA, Post RM. SPECT and PET imaging in mood disorders. Nov suppl 6–13

Gierl B see Davis JM

Gittelman DK, Kirby MG. Seizure following bupropion overdose [letter]. Apr 162

Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. Feb suppl 16–22

Glazer WM. Introduction: psychotic relapse: a multisystems perspective. Mar suppl 3–4

Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Apr 133–139

Goisman RM, Rogers MP, Steketee GS, Warshaw MG, Cuneo P, Keller MB. Utilization of behavioral methods in a multicenter anxiety disorders study. June 213–218

Gold DD Jr. Review of Kerwin R (ed): *Neurobiology and Psychiatry: Volume 1.* Mar 118

Gold DD Jr. Review of Lindenmayer J-P, Kay SR (eds): *New Biological Vistas on Schizophrenia.* Nov 443

Gold DD Jr. Review of Mednick SA, Cannon TD, Barr CE, Lyon M (eds): *Fetal Neural Development and Adult Schizophrenia.* May 204

Goldstein DJ, Rampey AH Jr, Potvin JH, Masica DN, Beasley CM Jr. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Aug 309–316

Golwyn DH, Sevlie CP. Adventitious change in homosexual behavior during treatment of social phobia with phenelzine [letter]. Jan 39–40

Goodman E see Downs JM

Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive compulsive disorder. June suppl 16–26

Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. Jan 13–20

Gorman JM see Coplan JD

Gottesman HG, Schubert DSP. Low-dose oral medroxyprogesterone acetate in the management of the paraphilias. May 182–188

Gratz SS, Simpson GM. MAOI-narcotic interactions [letter]. Nov 439

Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. Aug suppl 39–45

Greenberg D see Heresco-Levy U

Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. Nov 419–424

Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Economic burden of depression in 1990. Nov 405–419

Greenblatt DJ. Basic pharmacokinetic principles and their application to psychotropic drugs. Sept suppl 8–13. Correction, Nov 442

Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Oct suppl 4–14

Greist JH see Jefferson JW

Griffin-Francell C see Domenici N

Griffin M see Warner MD

Griffiths RR see Sellers EM

Grosso T. Review of Straussner SLA (ed): *Occupational Social Work Today.* Sept 358

Gude T see Hoffart A

Gulley LR, Nemeroff CB. Neurobiological basis of mixed depression-anxiety states. Jan suppl 16–19

Gutheil C see Ratey JJ

Hale AS. New antidepressants: use in high-risk patients. Aug suppl 61–70

Haller E. Successful management of patients with "multiple chemical sensitivities" on an inpatient psychiatric unit. May 196–199

Hamilton MS see Opler LA

Hanson DR see Roerig JL

Harmatz JS see Greenblatt DJ

Harney JH, Fulton C, Ross ED, Rush AJ. Dexamethasone suppression test and onset of poststroke depression in patients with ischemic infarctions. Sept 343–348

Hassan M see Davis JM

Haviland MG see Cummings MA

Heikkinen H, Outakoski J, Merilainen V, Tuomi A, Huttunen MO. Molindone and weight loss [letter]. Apr 160–161

Heimberg RG. Specific issues in the cognitive-behavioral treatment of social phobia. Dec suppl 36–45

Hendricks SE see Balogh S

Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. Feb 59–62

Hipsley PA see Hoehn-Saric R

Hoehn-Saric R, McLeod DR, Zimmerli WD, Hipsley PA. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. July 272–276

Hoffart A, Due-Madsen J, Lande B, Gude T, Bille H, Torgersen S. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. Dec 481–487

Hogarty GE. Prevention of relapse in chronic schizophrenic patients. Mar suppl 18–23
Hollander E, Hwang MY. Reply to Terao T: Titration of serotonin reuptake blockers [letter]. Mar 115
Hollander E see Stein DJ
Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. Feb 47–54
Hudson JI see McElroy SL
Huessy HR. Review of Greenhill LL, Osman BB (eds): *Ritalin: Theory and Patient Management*. Mar 117
Huessy HR. Review of Marsh DT: *Families and Mental Retardation: New Directions in Professional Practice*. Nov 444
Hughes AR see Walker PW
Hughes JR. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Mar 109–114
Huttunen MO see Heikkinen H
Hwang MY see Hollander E
Ibáñez-Rojo V see Iruela LM
Iruela LM, Caballero L, Ibáñez-Rojo V, Palanca I. Paniclike symptoms after veralipride withdrawal [letter]. Dec 488–489
Jacobs SC see Rosenstein DL
Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. June 229–234
Jacobsen FM. Reply to Balon R: Fluoxetine-induced sexual dysfunction and yohimbine [letter]. Apr 161–162
Janicak PG. Relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. Sept suppl 35–41
Jefferson JW, Greist JH. Converting from Lithobid to other lithium preparations [letter]. Oct 396–397
Jefferson JW see Maddock RJ
Jessee SS. Review of Castelnuovo-Tedesco P: *Dynamic Psychiatry: Explorations in Psychotherapy, Psychoanalysis, and Psychosomatic Medicine*. Apr 163–164
Joffe RT, Schuller DR. Open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. July 269–271
Joffe RT see Cooke RG
Johnston JA see Walker PW
Jonas JM, Cohon MS. Comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Oct suppl 25–45
Kahn RS see Galynker I
Kales A see Vgontzas AN
Kando JC see Cole JO
Kane JM. Reply to Peterson GN: Psychopharmacological screening criteria [letter]. Oct 398
Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? Sept 327–330
Kane JM see Davis JM
Kaplan Z see Zohar J
Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. Aug 305–308
Keck PE Jr see McElroy SL
Keller MB. Concluding remarks. Feb suppl 29–33
Keller MB. Difficult depressed patient in perspective. Feb suppl 4–8
Keller MB. Introduction. Managing the difficult depressed patient. Feb suppl 3
Keller MB see Goisman RM
Kellner C see Laird LK
Kellner CH, Pritchett JT, Beale MD. Electroconvulsive therapy as a treatment for recurrent depression [letter with reply]. Nov 441–442
Ketter TA see George MS
Khatain KG see Lacy TJ
Kilmer D see Ratey JJ
Kirby MG see Gittelman DK
Klein DF see Fallon BA
Klein RG see Pine DS
Klesmer J see Fricchione GL
Kloss RJ see DeQuardo JR
Knell ER, Comings DE. Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. Sept 331–337
Kolbrener ML see Strakowski SM
Kornhuber J see Weller M
Kosten TR see Sellers EM
Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: a review of risks and benefits. Oct suppl 78–84
Krishnan KRR see Davidson JRT; Maddock RJ; Potts NLS
Kumar A. Functional brain imaging in late-life depression and dementia. Nov suppl 21–25
Kupfer DJ. Management of recurrent depression. Feb 29–33
Kupfer DJ see Nofzinger EA
Lacy TJ, Khatain KG. Obsessive compulsive disorder manifesting as demonic attack [letter]. Oct 398
Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. June 224–228
Landbloom R see Roerig JL
Lande B see Hoffart A
Landy DA. HLA typing costs [letter with reply]. June 236
Lannon RA see Louie AK
Larson EW. Migraine with typical aura associated with fluoxetine therapy: case report [letter]. June 235–236
Lask B, Fosson A, Rolfe U, Thomas S. Zinc deficiency and childhood-onset anorexia nervosa. Feb 63–66
Lavallee Y-J see Boulenger J-P
Lazarus LW. Reply to Masand PS: Psychostimulants, poststroke depression, and side effects [letter]. Sept 356
Leaf PJ see Sholomskas DE
Lee S see Wong MK
Lenane MC see Rapoport JL
Leonard BE. Comparative pharmacology of new antidepressants. Aug suppl 3–15. Correction, Dec 491
Leonard HL see Rapoport JL
Leong GB see Silva JA
Lerer B see Heresco-Levy U
Leveroni C see Ratey JJ
Levine SB. Review of Mezey GC, King MB (eds): *Male Victims of Sexual Assault*. Sept 358
Levitt AJ see Cooke RG
Levitte SS see Smith DM
Lewis CP see Maddock RJ
Lewis TB see Louie AK
Lieberman JA. Prediction of outcome in first-episode schizophrenia. Mar suppl 13–17
Lieberman JA see Kane JM; Szymanski S
Liebowitz MR. Depression with anxiety and atypical depression. Feb suppl 10–14
Liebowitz MR. Mixed anxiety and depression: should it be included in DSM-IV? May suppl 4–7
Liebowitz MR. Pharmacotherapy of social phobia. Dec suppl 31–35
Liebowitz MR see Fallon BA; Maddock RJ
Liebowitz NR, El-Mallakh RS. Cardiac arrest during ECT: a cholinergic phenomenon? [letter] July 279–280
Lindy DC see Pine DS
Lineberry CG see Walker PW
Little KY. *d*-Amphetamine versus methylphenidate effects in depressed inpatients. Sept 349–355
Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. Nov 435–438
Lunsky LL. Review of Lamb HR, Bachrach LL, Kass FI (eds): *Treating the Homeless Mentally Ill*. Apr 164
Lydiard RB see Laird LK
Maddock RJ, Carter CS, Blacker KH, Beitman BD, Krishnan KRR, Jefferson JW, Lewis CP, Liebowitz MR. Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Mar 88–95
Mancini C see Van Ameringen M
Marder SR see Davis JM
Markovitz PJ. Treatment of anxiety in the elderly. May suppl 64–68
Marshall RD see Pine DS
Masand PS. Psychostimulants, poststroke depression, and side effects [letter with reply]. Sept 356
Masica DN see Goldstein DJ
McDougle CJ see Goodman WK
McElroy SL, Phillips KA, Keck PE Jr, Hudson JI, Pope HG Jr. Body dysmorphic disorder: does it have psychotic subtype? Oct 389–395
McElroy SL see Keck PE Jr
McGrath RE, Yahia M. Preliminary data on seasonally related alcohol dependence. July 260–262
McLeod DR see Hoehn-Saric R
McNamara ME see Campbell JJ
Melo A see de Oliveira IR
Merilainen V see Heikkinen H
Mitchell JE see Christenson GA
Mojtabai R see Sanati M
Moran MG see Stoudemire A
Morgenstern H see Glazer WM
Morris R see Rothbaum BO
Morton WA see Laird LK
Munn NA. Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [letter]. Nov 439–440

Myers WC, Burket RC, Otto TA. Conduct disorder and personality disorders in hospitalized adolescents. Jan 21–26
Nelson JC. Combined treatment strategies in psychiatry. Sept suppl 42–49
Nelson JC see Rosenstein DL
Nemeroff CB see Gulley LR
Newman AJ see Kravitz HM
Nields JA see Fallon BA
Ninan PT see Rothbaum BO
Nofzinger EA, Buysse DJ, Reynolds CF III, Kupfer DJ. Sleep disorders related to another mental disorder (nonsubstance/primary): a DSM-IV literature review. July 244–255
North CS see Smith EM
O'Brien DW see Sholomskas DE
Opler LA, Hamilton MS. Reply to Pearlman CA: Akathisia as EPS [letter]. July 280
Otto TA see Myers WC
Outakoski J see Heikkinen H
Palanca I see Iruela LM
Parsons B see Fallon BA
Pato MT see Rasmussen SA
Patterson L see Davidson JRT
Patterson WM. Fluoxetine-induced sexual dysfunction [letter]. Feb 71
Patterson WM. Review of Kernodle WD: *Panic Disorder: What You Don't Know May Be Dangerous To Your Health*. Dec 492
Peabody CA see Warner MD
Pearlman CA. Akathisia as EPS [letter with reply]. July 280
Pecknold J see Ballenger JC
Pereira EL see de Oliveira IR
Peralta V see de Leon J
Percudani M see Altamura AC
Perr IN. Review of Campion FX (ed): *Grand Rounds on Medical Malpractice*. Feb 75
Perr IN. Review of Johnson KB, Hatlie MJ, Johnson ID: *The Guide to Medical Professional Liability Insurance*. Feb 74
Perr IN. Review of Simon RI (ed): *Review of Clinical Psychiatry and the Law, vol. 3*. Feb 74–75
Peterson GN. Psychopharmacological screening criteria [letter with reply]. Oct 397
Pfister GM see Roerig JL
Phillips KA see McElroy SL
Pine DS, Klein RG, Lindy DC, Marshall RD. Attention-deficit hyperactivity disorder and comorbid psychosis: a review and two clinical presentations. Apr 140–145
Pohl R see Balon R
Pohlmann-Eden B see Forstl H
Pollack S see Kane JM
Pope HG Jr see McElroy SL
Popkin MK. Reply to Landy DA: HLA typing costs [letter]. June 236–237
Popkin MK see Roerig JL
Popper CW. Psychopharmacologic treatment of anxiety disorders in adolescents and children. May suppl 52–63
Post RM see George MS
Potts NLS, Davidson JRT, Krishnan KRR. Role of nuclear magnetic resonance imaging in psychiatric research. Dec suppl 13–18
Potts NLS see Davidson JRT
Potvin JH see Goldstein DJ
Preskorn SH. Introduction. Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. Sept suppl 3–8
Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Sept suppl 14–34
Preskorn SH, Fast GA. Beyond signs and symptoms: the case against a mixed anxiety and depression category. Jan suppl 24–32
Preskorn SH, Fast GA. Reply to Forstl H: Monitoring antidepressant-induced cerebral hyperexcitability [letter]. May 201–202
Preud'homme XA see Glassman AH
Price LH see Goodman WK
Pritchett JT see Kellner CH
Pyle RL see Christenson GA
Rabkin JG see Wagner GJ
Rabkin R see Wagner GJ
Raj BA, Corvea MH, Dagon EM. Clinical characteristics of panic disorder in the elderly: a retrospective study. Apr 150–155
Ramesh C see Balon R
Rampey AH Jr see Goldstein DJ
Rapoport JL, Leonard HL, Swedo SE, Lenane MC. Obsessive compulsive disorder in children and adolescents: issues in management. June suppl 27–29
Rasmussen KG, Zorumski CF. Electroconvulsive therapy in patients taking theophylline. Nov 427–431
Rasmussen SA. Introduction. Diagnosis and treatment of OCD: a clinician's perspective. June suppl 3
Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. June suppl 4–9. Correction, Dec 491
Rasmussen SA see Eisen JL
Rakel RE. Introduction. Part II. Treatment strategies for complicated anxiety. May suppl 21
Ratey JJ, Leveroni C, Kilmer D, Gutheil C, Swartz B. Effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. June 219–223
Reba RC. PET and SPECT: Opportunities and challenges for psychiatry. Nov suppl 26–32
Reiman EM see Baxter LR
Reynolds CF III see Nofzinger EA
Ribeiro M see de Oliveira IR
Rickels K, Schweizer E. Treatment of generalized anxiety disorder in patients with depressive symptomatology. Jan suppl 20–23
Rickels K see Ballenger JC; Freeman EW
Rieck SO see Wise MG
Roerig JL, Hanson DR, Landbloom R, Pfister GM, Popkin MK. Reply to Landy DA: HLA typing costs [letter]. June 236–237
Rogers MP see Goisman RM
Rolfe U see Lask B
Romach MK see Schadel M; Sellers EM
Rosenbaum JF see Sichel DA
Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. Aug 289–299
Ross ED see Harney JH
Ross J. Social phobia: the consumer's perspective. Dec suppl 5–9
Rothbaum BO, Shaw L, Morris R, Ninan PT. Prevalence of trichotillomania in a college freshman population [letter with reply]. Feb 72
Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. Sept 338–342
Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. Sept suppl 50–54
Ruiz P. Review of Garza-Treviño ES (ed): *Medical Psychiatry: Theory and Practice*. Apr 164. Correction, June 238
Rush AJ see Harney JH
Safferman A see Szymanski S
Safferman AZ see Kane JM
Salehmoghaddam S see Strouse TB
Salzman C. Pharmacologic treatment of depression in the elderly. Feb suppl 23–28
Samson JA see Rothschild AJ
Sanati M, Mojtabai R. Fregoli syndrome with a jealous theme. Dec 490–491
Sandoval R see Goodnick PJ
Santiago JM. Commentary: the costs of treating depression. Nov 425–426
Satel SL. Diagnostic limits of "addiction" [letter with reply]. June 237
Schadel M, Romach MK, Sellers EM. Mania and cough syrup [letter]. May 200
Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. Oct 380–384
Scharf MB. Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. Jan 33–38
Schooler N see Davis JM
Schubert DSP see Gottesman HG
Schuller DR see Joffe RT
Schweizer E see Rickels K
Sellers EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE. Alprazolam and benzodiazepine dependence. Oct suppl 64–75
Sellers EM see Ballenger JC; Schadel M
Serafetinides EA. EEG in psychiatry [letter]. Oct 397
Serban G. Reply to DeQuardo JR: Contribution of anticholinergic medication to symptom change in schizophrenia [letter]. Sept 357
Settle EC Jr. Akathisia and sertraline [letter]. Aug 321
Sevlie CP see Golwyn DH
Shader RI see Greenblatt DJ
Shaw L see Rothbaum BO
Shelton RC see Strakowski SM
Sholomskas DE, Wickamaratne PJ, Dogolo L, O'Brien DW, Leaf PJ, Woods SW. Postpartum onset of panic disorder: a coincidental event? Dec 476–480
Short DD see Workman EA
Shuchter SR see Zisook S
Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF. Postpartum obsessive compulsive disorder: a case series. Apr 156–159
Silva JA, Leong GB. Case of organic Othello syndrome [letter]. July 277
Simpson GM see Gratz SS

Skowron DM, Tornatore FL. More on nonphysician prescribers [letter with reply]. Oct 396

Smith DM, Levitte SS. Association of fluoxetine and return of sexual potency in three elderly men. Aug 317–319

Smith EM, North CS, Spitznagel EL. Alcohol, drugs, and psychiatric comorbidity among homeless women: an epidemiologic study. Mar 82–87

Sondheimer SJ see Freeman EW

Sovner R, Bailey KP. Reply to Skowron DM: More on nonphysician prescribers [letter]. Oct 396

Spar JE see Strouse TB

Spier SA, Frontera MA. Reply to Fricchione GL: Vasoconstrictive effects and SSRIs [letter]. Feb 72

Spitznagel EL see Smith EM

Stahl SM. Mixed anxiety and depression: clinical implications. Jan suppl 33–38

Stanziani P see Ellison JM

Steele TE see Laird LK

Stein DJ, Hollander E. Reply to Satel SL: Diagnostic limits of "addiction" [letter]. June 237–238

Stein LI. System approach to reducing relapse in schizophrenia. Mar suppl 7–12

Steketee GS see Goisman RM

Stiglin LE see Greenberg PE

Stokes PE. Primary care perspective on management of acute and long-term depression. Aug suppl 74–84

Stone AB. Treatment of hypochondriasis with clomipramine [letter]. May 200–201

Stoudemire A, Moran MG. Psychopharmacologic treatment of anxiety in the medically ill elderly patient: special considerations. May suppl 27–33

Stovall JG. Review of Morse WC (ed): *Crisis Intervention in Residential Treatment: The Clinical Innovations of Fritz Redl.* Feb 75–76

Strakowski SM, Shelton RC, Kolbrener ML. Effects of race and comorbidity on clinical diagnosis in patients with psychosis. Mar 96–102

Streiner DL see Van Ameringen M

Strouse TB, Salehmoghaddam S, Spar JE. Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient [letter]. Dec 488–490

Surawicz FG. Review of Hamilton JA, Harberger PN: *Postpartum Psychiatric Illness: A Picture Puzzle.* Aug 322

Surawicz FG. Review of Stern EM (ed): *Psychotherapy and the Widowed Patient.* Jan 41

Surawicz FG. Review of Yaeger J, Gwirtsman HE, Edelstein CK (eds): *Special Problems in Managing Eating Disorders.* Feb 76

Sussman N. How to manage anxious patients who are depressed. May suppl 8–16

Sussman N. Treating anxiety while minimizing abuse and dependence. May suppl 44–51

Swann AC see Walls MJ

Swartz B see Ratey JJ

Swartz CM. Advancing age may inhibit antidepressant-induced seizure. May 202

Swedo SE see Rapoport JL

Szymanski S, Lieberman JA, Safferman A, Galkowski B. Rib fractures as an unusual complication of severe tardive dystonia [letter]. Apr 160

Tanay E. Review of Appelbaum PS, Gutheil TG (eds): *Clinical Handbook of Psychiatry and the Law, 2nd ed.* Feb 76

Tancer ME. Neurobiology of social phobia. Dec suppl 26–30

Terao T. Titration of serotonin reuptake blockers [letter with reply]. Mar 115

Thase ME. Reply to Kellner CH: Electroconvulsive therapy as a treatment for recurrent depression [letter]. Nov 441–442

Thomas S see Lask B

Thompson NM see Laird LK

Tiffon L see Coplan JD

Tohen M see Banov MD

Tollefson GD. Adverse drug reactions/interactions in maintenance therapy. Aug suppl 48–58

Torgersen S see Hoffart A

Tornatore FL see Skowron DM

Tugrul KC see Keck PE Jr

Tuomi A see Heikkinen H

Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. Jan 27–32

Veeser WR. Review of Stoloff ML, Brewster J, Couch JV: *Hardware, Software, and the Mental Health Professional: The Complete Guide to Office Computerization.* June 239

Vela-Bueno A see Vgontzas AN

Verbosky LA, Franco KN, Zrull JP. Relationship between depression and length of stay in the general hospital patient. May 177–181

Vgontzas AN, Kales A, Bixler EO, Vela-Bueno A. Commentary: sleep disorders related to another mental disorder (non substance/primary): a DSM-IV literature review. July 256–259

Vlay SC see Fricchione GL

von Moltke LL see Greenblatt DJ

Wagner GJ, Rabkin JG, Rabkin R. Sexual activity among HIV-seropositive gay men seeking treatment for depression. Dec 470–475

Walker PW. Review of Kennedy JA: *Fundamentals of Psychiatric Treatment Planning.* Nov 443

Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, Lineberry CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Dec 459–465

Walls MJ, Bowers TC, Dilsaver SC, Swann AC. Catatonia associated with depression secondary to complex partial epilepsy [letter]. Feb 73

Wareham JG see Cummings MA

Warner MD, Griffin M, Peabody CA. High initial nortriptyline doses in the treatment of depression. Feb 67–69

Warshaw MG see Goisman RM

Weinberger DR. SPECT imaging in psychiatry: introduction and overview. Nov suppl 3–5

Weise RE. Review of Bauer GP (ed): *Wit and Wisdom in Dynamic Psychotherapy.* Aug 322

Weller M, Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? [letter] Feb 70–71

Wesner R see Black DW

Wickamaratne PJ see Sholomskas DE

Wise MG, Rieck SO. Diagnostic considerations and treatment approaches to underlying anxiety in the medically ill. May suppl 22–26

Wittchen H-U, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? Jan suppl 9–15

Woerner MG see Kane JM

Wong MK, Lee S. Nadolol in the treatment of aggression in chronic psychiatric inpatients [letter]. June 235

Woods SW see Sholomskas DE

Woody GE see Sellers EM

Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Jan 5–12

Woznicki RM see Fricchione GL

Yahia M see McGrath RE

Yeragani VK see Balon R

Zajecka JM see Schaff MR

Zimmerli WD see Hoehn-Saric R

Zisook S, Shuchter SR. Uncomplicated bereavement. Oct 365–372

Zohar J, Kaplan Z, Benjamin J. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients. Oct 385–388

Zorumski CF see Rasmussen KG

Zrull JP see Verbosky LA